Sun Pharma Releases New Anti-Cancer Drug Palbociclib In India

Share Us

795
Sun Pharma Releases New Anti-Cancer Drug Palbociclib In India
11 Jan 2023
5 min read

News Synopsis

In India, Sun Pharma launches the new anti-cancer drug Palbociclib. Through an exchange filing, Sun Pharmaceutical Industries Limited said that one of its fully-owned subsidiaries had introduced the revolutionary anti-cancer medication Palbociclib for patients with advanced breast cancer, the most common type of cancer among women in India.

The company will market the medication as PALENO (Palbociclib) 75 mg, 100 mg, and 125 mg. For patients with hormone receptor-positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer, palbociclib is approved by the USFDA, EMA, and CDSCO in combination with hormonal therapies.

Kirti Ganorkar, CEO of Sun Pharma's India Business, said  "We are introducing Palbociclib at an affordable price which will help improve patient access. PALENO will address the treatment need of several advanced breast cancer patients in India. For the first time, we are introducing a unique patient assistance programme that will improve patient compliance and accessibility."

Sun Pharmaceutical Industries Limited, comprising its affiliates and subsidiaries (Sun Pharma), is the top-ranked speciality generic company in both India and the US, coming in at number four overall. It ranks as one of the top Indian pharmaceutical businesses in emerging markets and is the biggest in the US.

The business produces and sells a wide range of pharmaceutical formulations for both acute and chronic treatments. It covers over-the-counter (OTC) medications, anti-retrovirals (ARVs), branded generics, sophisticated or challenging-to-manufacture goods, active pharmaceutical ingredients (APIs), and intermediates. More than 2000 high-quality compounds are included in the product portfolio, which also includes tablets, capsules,  injectables, inhalers, ointments, lotions, and liquids among other dosage forms.

TWN News Network